Maybe news??? Would that be good news or bad news?
Will
Maybe news??? Would that be good news or bad news?
Will it be Dr. Recknors “very soon” news? Will it be accompanied by a partnership or not?
So many scenarios to contemplate. Does anyone have a grip on what’s going to happen? Is there a blooming happening in April Shelly? Will this 10Q be released after market closes? Most likely.
The show will be Tuesday for up or down on Stock Price. Tomorrow brings much speculation about the 10Q. The adjustment to the price is definitely Tuesday. The only question is will it go up or go down and how much…
I have a dream… lets say that there is a PR before market opens Monday telling us that we have a partner for NAFLD/NASH with the best results in a phase 2 trial that has ever happened so far in pharmaceutical history of Nash trials. That partnership is with a well known company we have dealt with before. One that wants to get into the pharmaceutical business and not just manufacture.
Wouldn’t this be a big welcomed surprise if it was Samsung and they become our rich big brother and only want a partnership for just NAFLD/NASH. The news of partnership ends up repairing our relationship with our manufacturing buddy and Samsung gives us the upfront monies to accomplish a nice phase 3 trial with all the bells and whistles of biopsies and all 4 of the trial markers we used in the phase 2 trial. Enough up front milestone money that dilution is not needed the rest of the year. Our only focus becomes the new Nash trial. The biopsies before trial and after of the liver being the golden goose egg we need to acquire for the FDA to get our BLA for what could be the best and only drug ever to show a reversal of the fibrosis of the liver.
I want to dream tonight in bed… about… it’s almost time to start calculating the worlds population of over 9 billion with 30% having NAFLD and 3-10% having Nash. Let’s see how much that adds up to with weekly injections of Leronlimab for over 3 Billion people… hmmm. Calculators just don’t carry enough spaces for calculations like this. Show me another drug in the world that would touch 10-30% of the worlds population… there isn’t one… there is not even a drug that comes close to 1% of the worlds population. ohhhh… this is what dreams are made of…
Then we spend all afternoon and evening dissecting how many people will be needed in a phase 3 BTD confirmation trial, how long this will take and will they apply for a the BTD to move the pace up on revenue and then… When will you buy your first toy and or maybe buy Putin’s summer Cottage on the Black Sea. Naw… who could afford a 2 billion dollar tiny cottage with its own inside professional hockey arena.
Then I wake up and none of it’s true as it was just a dream and we start speculating anyways because there is no information of importance in the 10Q… and Recknor can’t release any information just yet. NDA’s are being respected and we wait patiently like we have for the last 3 months… damn… that was a nightmare not a dream… but there is hope a dream can happen… did I say that right??? There is hope a dream can happen. I will go to sleep tonight hoping for a dream like I hoped for and not a nightmare. The ride has been hard and long enough… we need some really great news this week. Let’s hope! The world needs our hope!
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...
Continue Reading
A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...
Continue Reading
They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...
Continue Reading
Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...
Continue Reading
Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...
Continue Reading
Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...
Continue Reading
Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....
Continue Reading
Top 5 Most Recently Viewed Articles
Alpha Omega snagged the Best Digital Transformation Award at the Unqork Hackathon, and it’s turning heads across the tech landscape. This ain't just a shiny trophy; it's a nod to how serious they are about shaking up federal government operations with some cutting-edge tech magic. But let’s break down what this really means for traders eyeing the public sector's...
Continue Reading
Novo Nordisk kicked off a hefty share repurchase program back in early February 2024, aimed at boosting shareholder value with a staggering DKK 20 billion on the table. This move isn’t just fluff; it screams confidence from the boardroom about their future prospects. The whole plan is not just about buying back shares; it's a strategic play to manage capital efficiently...
Continue Reading
Ease.io's Remarkable Q2 Performance Highlights Key Achievements Ease.io, a frontrunner in audit and inspection software designed specifically for manufacturers, has reported impressive growth in its latest quarterly performance. The company has not only exceeded its projections but has also secured major enterprise clients while expanding its product offerings. This...
Continue Reading
Strategic Acquisition Marks a New Chapter for Salesfloor Salesfloor, a leader in Clienteling and virtual shopping solutions, has recently taken a significant step forward by acquiring Clientela. This strategic acquisition expands Salesfloor’s market reach and enhances its already robust platform, aimed at engaging customers with cutting-edge technology. Enhancing...
Continue Reading
Welch's Appoints Christine Kwiat as Chief Research and Development Officer Welch's, a prominent player in the fruit-based food and beverage scene, has recently announced an important leadership change. Christine Kwiat has been named the Chief Research and Development Officer, and her appointment is effective immediately. She steps into this pivotal role with a vision for...
Continue Reading